<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057897</url>
  </required_header>
  <id_info>
    <org_study_id>D8111C00010</org_study_id>
    <nct_id>NCT05057897</nct_id>
  </id_info>
  <brief_title>A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults</brief_title>
  <acronym>VICTORIA</acronym>
  <official_title>A Phase IV Open-Label, Non-Randomized, Multi-Cohort, Multicenter Study in Previously Unvaccinated Immunocompromised Adults to Determine the Immunogenicity and Safety of AZD1222 Vaccine for the Prevention of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the immunogenicity and safety of AZD1222 for prevention of&#xD;
      COVID-19 in immunocompromised adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to demonstrate the safety and characterize the immunogenicity of&#xD;
      AZD1222; AstraZeneca's candidate ChAdOx1 vector vaccine against SARS-CoV-2 (nCoV-19) in&#xD;
      previously unvaccinated immunocompromised adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 22, 2021</start_date>
  <completion_date type="Anticipated">July 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Previously unvaccinated immunocompromised adults will be enrolled in 5 disease cohorts of approximately 60 participants each:&#xD;
Solid organ transplant&#xD;
Hematopoietic stem cell transplant&#xD;
Solid organ cancer patients receiving cytotoxic chemotherapy&#xD;
Chronic inflammatory disorders&#xD;
Primary immunodeficiency A sixth cohort of immunocompetent individuals will also be recruited. Participants will be allocated to the immunocompromised cohorts according to the underlying aetiology of their immunocompromised status.&#xD;
Participants will receive 2 intramuscular doses of AZD1222 separated by 4 weeks and will be followed for 1 year after dose 1.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 specific titres in SARS-CoV-2 naïve immunocompromised adults and immunocompetent adults ≥ 18 years</measure>
    <time_frame>28 days after dosing</time_frame>
    <description>Characterization of immunogenicity of a 2-dose primary vaccination with AZD1222 with a 4-week dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroresponse of SARS-CoV-2 specific titres (≥ 4-fold rise in titres from baseline) in SARS-CoV-2 naïve immunocompromised adults and immunocompetent adults ≥ 18 years</measure>
    <time_frame>28 days after dosing</time_frame>
    <description>Characterization of immunogenicity of a 2-dose primary vaccination with AZD1222 with a 4-week dosing interval</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of SARS-CoV-2 specific GMT titres in adults ≥ 18 years with a 4-week dosing interval between SARS-CoV-2 naïve participants in the comparator cohort as compared with immunocompetent participants</measure>
    <time_frame>28 days after Dose 2</time_frame>
    <description>Description of the immunogenicity of a 2-dose primary vaccination with AZD1222&#xD;
Comparator cohorts:&#xD;
solid organ transplant/hematopoietic stem cell transplant/solid organ cancer patients receiving cytotoxic chemotherapy/chronic inflammatory disorders/primary immunodeficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in seroresponse rates of SARS-CoV-2 specific titres in adults ≥ 18 years with a 4-week dosing interval between SARS-CoV-2 naïve participants in the comparator cohort as compared with immunocompetent participants</measure>
    <time_frame>28 days after Dose 2</time_frame>
    <description>Description of the immunogenicity of a 2-dose primary vaccination with AZD1222, with a difference of ≥ 4-fold rise in titres from baseline&#xD;
Comparator cohorts:&#xD;
solid organ transplant/hematopoietic stem cell transplant/solid organ cancer patients receiving cytotoxic chemotherapy/chronic inflammatory disorders/primary immunodeficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of SARS-CoV-2 specific GMT titres in adults ≥ 18 years with a 4-week dosing interval between SARS-CoV-2 naïve participants with any immunocompromised condition compared to immunocompetent participants</measure>
    <time_frame>28 days after Dose 2</time_frame>
    <description>Description of the immunogenicity of a 2-dose primary vaccination with AZD1222</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in seroresponse rates of SARS-CoV-2 specific titres in adults ≥ 18 years with a 4-week dosing interval between SARS-CoV-2 naïve participants with any immunocompromised condition compared to immunocompetent participants</measure>
    <time_frame>28 days after Dose 2</time_frame>
    <description>Description of the immunogenicity of a 2-dose primary vaccination with AZD1222, with a difference of ≥ 4-fold rise in titres from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of local and systemic solicited AEs after dosing in SARS-CoV-2 naïve immunocompromised adults ≥ 18 years</measure>
    <time_frame>For 7 days after each dose of AZD1222</time_frame>
    <description>Characterization of the reactogenicity and safety of a 2-dose primary vaccination with AZD1222 with a 4-week dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of unsolicited AEs after dosing in SARS-CoV-2 naïve immunocompromised adults ≥ 18 years</measure>
    <time_frame>For 28 days post dose after each vaccination (i.e., until Day 29 following the first vaccination and Day 57 following the second vaccination)</time_frame>
    <description>Characterization of the reactogenicity and safety of a 2-dose primary vaccination with AZD1222 with a 4-week dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SAEs, MAAEs and AESIs in SARS-CoV-2 naïve immunocompromised adults ≥ 18 years</measure>
    <time_frame>From Day 1 post treatment to Day 365</time_frame>
    <description>Characterization of the reactogenicity and safety of a 2-dose primary vaccination with AZD1222 with a 4-week dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and change from baseline for safety laboratory measures in SARS-CoV-2 naïve immunocompromised adults ≥ 18 years</measure>
    <time_frame>During the study</time_frame>
    <description>Characterization of the reactogenicity and safety of a 2-dose primary vaccination with AZD1222 with a 4-week dosing interval</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>COVID-19, SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>2 doses of AZD1222, 4 weeks apart</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Previously unvaccinated. First dose administered on Day 1 and second dose on Day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AZD1222</intervention_name>
    <description>10 mM histidine, 7.5% (w/v) sucrose, 35 mM sodium chloride, 1 mM magnesium chloride, 0.1% (w/v) polysorbate 80, 0.1 mM edetate disodium, 0.5% (w/v) ethanol, at pH 6.6</description>
    <arm_group_label>2 doses of AZD1222, 4 weeks apart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult, ≥ 18 years at the time of signing the informed consent.&#xD;
&#xD;
          2. Cohort specific inclusion criteria:&#xD;
&#xD;
        Solid organ transplant&#xD;
&#xD;
          -  Participants with heart, lung, kidney, or liver transplant, and are stable on&#xD;
             immunosuppressants (defined as no change in dose in the previous 4 weeks).&#xD;
&#xD;
        Hematopoietic stem cell transplant&#xD;
&#xD;
          -  Participants with autologous (up to 6 months after transplantation) or allogeneic stem&#xD;
             cell transplant who are immunosuppressed, with no evidence of active graft-versushost&#xD;
             disease, at least one month after the procedure.&#xD;
&#xD;
        Cancer patients on chemotherapy&#xD;
&#xD;
          -  Participants with solid tumors (except breast cancer), histologically diagnosed, who&#xD;
             were undergoing intravenous cytotoxic chemotherapy within the last 6 months, who&#xD;
             received at least 1 cycle prior to cytotoxic chemotherapy, and have a life expectancy&#xD;
             of longer than 3 months.&#xD;
&#xD;
        Chronic inflammatory conditions&#xD;
&#xD;
          -  Participants with chronic inflammatory conditions, including those on&#xD;
             immunosuppressant medications, can be recruited. The following conditions are&#xD;
             specifically excluded: multiple sclerosis and peripheral demyelinating disease.&#xD;
&#xD;
        Primary immune deficiency&#xD;
&#xD;
          -  Examples include combined granulomatous disorder, SCID, common variable&#xD;
             immunodeficiency.&#xD;
&#xD;
        Immunocompetent:&#xD;
&#xD;
          -  No confirmed or suspected immunosuppressive or immunodeficient state.&#xD;
&#xD;
          -  No use of immunosuppressant medication within the past 1 month (≥ 20 mg per day of&#xD;
             prednisone or its equivalent, given daily or on alternate days for ≥ 15 days within 30&#xD;
             days prior to administration of AZD1222). The following exceptions are permitted:&#xD;
             topical/inhaled steroids or short-term oral steroids (course lasting ≤ 14 days).&#xD;
&#xD;
          -  No receipt of immunoglobulins and/or any blood products within 3 months prior to&#xD;
             administration of AZD1222 or expected receipt during the period of study follow up.&#xD;
&#xD;
          -  No severe and/or uncontrolled cardiovascular disease, respiratory disease,&#xD;
             gastrointestinal disease, liver disease, renal disease, endocrine disorder, and&#xD;
             neurological illness, as judged by the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             AZD1222.&#xD;
&#xD;
          2. Active infection with SARS-CoV-2 as confirmed locally by RT-PCR.&#xD;
&#xD;
          3. Known past laboratory-confirmed SARS-CoV-2 infection.&#xD;
&#xD;
          4. Significant infection or other acute illness, including fever (temperature &gt; 37.8°C)&#xD;
             on the day prior to or day of first dosing.&#xD;
&#xD;
          5. Thrombocytopenia with platelet count ≤ 75,000 x 109/microliter based on complete blood&#xD;
             count test at screening visit.&#xD;
&#xD;
          6. HIV-positive participants based on a positive ELISA test performed at screening visit.&#xD;
&#xD;
          7. History of cerebral venous sinus thrombosis (CVST).&#xD;
&#xD;
          8. Receipt of any vaccine (licensed or investigational) within 30 days prior to and after&#xD;
             administration of AZD1222.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clínica de la Costa Ltda.</name>
      <address>
        <city>Barranquilla</city>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca</name>
      <address>
        <city>Floridablanca</city>
        <zip>6810002</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Oftalmologica de Santander - FOSCAL</name>
      <address>
        <city>Floridablanca</city>
        <zip>681004</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ESIC Medical College and Hospital</name>
      <address>
        <city>Faridabad</city>
        <state>Haryana</state>
        <zip>121012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shetty Hospital</name>
      <address>
        <city>Bengaluru</city>
        <state>Karnataka</state>
        <zip>560068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mavens Hospital</name>
      <address>
        <city>Ajmer</city>
        <state>Rajasthan</state>
        <zip>305001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Gleneagles Hospitals Ltd.</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok-noi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Pathumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNE Ivano-Frankivsk Reg Clin Infectious Hospital of Ivano-Frankivsk Regional Council</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76007</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pratia Clinic Ukraine LLC</name>
      <address>
        <city>Kharkiv</city>
        <zip>61052</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI &quot;Shalimov's National Institute of Surgery and Transplantation&quot; of NAMSU</name>
      <address>
        <city>Kyiv</city>
        <zip>03126</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Communal 4th City Clinical Hospital</name>
      <address>
        <city>Lviv</city>
        <zip>79011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>India</country>
    <country>Thailand</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

